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Ischemic stroke is one of the most common causes of death worldwide and is most often caused by thrombotic processes. We
investigated the changes in hsCRP and homocysteine levels, two of these risk factors, during the acute period of ischemic stroke
and evaluated the relationship between these levels and the short-term prognosis. HsCRP and homocysteine levels were measured
at the 2nd, 5th, and 10th days in forty patients admitted within second of an ischemic stroke. The clinical status of the patients was
simultaneouslyevaluatedwiththeScandinavianstrokescale.Theresultswerecomparedwith40healthycontrolsubjectswhoseage
and sex were matched with the patients. The mean hsCRP levels of the patients were 9.4±7.0m g / Lo nt h e2 n dd a y ,1 1 .0±7.4mg/L
on the 5th day, and 9.2 ± 7.0mg/L on the 10th day. The mean hsCRP level of the control subjects was 1.7 ± 2.9mg/L. The mean
hsCRP levels of the patients on the 2nd, 5th, and 10th days were signiﬁcantly higher than the control subjects (P<. 001). The
patients’meanhomocysteinelevelswere40.6±9.6µmol/Lonthe2ndday,21.7±11.1µmol/Lonthe5thday,and20.7±9.2µmol/L
on the 10th day. The mean homocysteine level of the control subjects was 11.2 ± 1.1µmol/L. The homocysteine levels of the
patients were higher than the control subjects at all times (P<. 01). In conclusion, patients with stroke have a higher circulating
serum hsCRP and homocysteine levels. Short-term unfavorable prognosis seems to be associated with elevated serum hsCRP
levels in patients with stroke. Although serum homocysteine was found to be higher, homocysteine seems not related to prog-
nosis.
Copyright © 2007 Tahir Yoldas et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Acute ischemic stroke develops as a result of a sudden inter-
ruption in the focal cerebral blood ﬂow [1, 2]. The cause of
the stroke is an embolic or thrombotic occlusion in 70–80%
of patients with severe symptoms [3, 4].
Recent research has shown that an inﬂammatory reac-
tion is triggered within hours in the brain tissue injured by
an ischemic stroke and continues in the days following the
appearance of symptoms and that this reaction contributes
to neuronal damage [5].
Increased CRP levels are accepted as a sensitive but non-
speciﬁc marker of the acute inﬂammatory response. CRP
levels can increase 100 to 500 folds in acute inﬂammatory
conditions [6]. Laboratory and experimental ﬁndings have
shown that atherosclerosis is a reﬂection of a chronic inﬂam-
matory process in addition to lipid deposition [7, 8]. Inﬂam-
matory mechanisms have been known to play a role in all
stages of atherosclerosis, from initiation to development [9–
12].
It has been reported that it is possible to use the increase
in the concentration of acute phase reactants and especial-
ly the high sensitivity C-reactive protein (hsCRP) to help
predict future cardiovascular morbidity [8, 12–14]. Various
prospective studies have found initial CRP levels to be higher
in persons who develop stroke, ischemic heart disease, and
peripheral artery disease [15–17].
There is increasing evidence that mild hyperhomocys-
teinemia is an independent risk factor for atherosclerosis and
atherothrombosis in the coronary, cerebral, and peripheral
vascular structures [17–20].
The aim of this study was to determine the acute course
of hsCRP and homocysteine levels following a stroke and
their association with the short-term prognosis. An increas-
ingamountofevidenceshowsthesesubstancestoberiskfac-
tors for atherosclerosis and therefore ischemic stroke.2 Mediators of Inﬂammation
Table 1: Mean SSS scores of patients(a).
Mean SSS
score
Patients Group A (independent walking) Group B (nonwalking) Group C (died patients)
n = 40 n = 15 (37.5%) n = 18 (45%) n = 7 (17.5%)
2nd day 26.4 ±15.0∗ 37.3 ±14.1∗ 20.8 ±10.21 3 .71 ±5.7
5th day 31.7 ±16.0∗ 45.8 ±10.7∗ 24.3 ±10.71 5 .06 ±3.7
(a)Mean ± standard deviation, ∗P<. 05.
2. MATERIAL AND METHOD
Atotalof40patientswhoseagemeanis69±11yearspresent-
ing at the Firat University Medical Faculty Neurology Out-
patients Department with a clinical picture of acute ischemic
stroke within the ﬁrst 2 days and admitted with a diagnosis
of ischemic stroke were included in the study. The control
group consisted of 40 healthy volunteers whose age mean is
70 ± 9 years who did not have any deﬁned illnesses and were
matched for age and sex with the patient group. The patient
a n dc o n t r o lg r o u ps u b j e c t sw e r ei n f o r m e do nt h es t u d y ,a n d
written consent was obtained.
A diagnosis of acute ischemic stroke was made following
a full neurological evaluation including the use of neuroradi-
ologic imaging such as CT and/or MRI in patients who had
suﬀered an acute focal neurologic deﬁcit for more than 24
hours and who did not have a cause other than cerebrovas-
cular disease for this neurological deﬁcit. The clinical status
of the patients was evaluated with the Scandinavian stroke
scale.
The medical history was obtained from the patients with
particular attention to deﬁned risk factors such as DM,
smoking, and dyslipidemia. Physical and neurological exam-
inations, CT and carotid-vertebral Doppler ultrasonograpy,
and other routine laboratory analyses were carried out on
allpatients.Patientswhoseneurologicalsymptomsimproved
within 24 hours, those receiving a diagnosis of hemorrhagic
cerebrovascular disease following clinical and neuroradio-
logic evaluation and those who had previously suﬀered an
ischemic stroke were not included in the study.
Patients who had heart disease which could lead to car-
dioembolism such as atrial ﬁbrillation or cardiac valve dis-
ease or thyroid or renal dysfunction or kidney failure, pa-
tients with local or systemic infection or those who had suf-
fered an infection within the last month, and those with ro-
matoid arthritis, osteoarthritis, or malignancy were not in-
cluded in the study. The patients were asked about the us-
age of drugs such as vitamin combinations, methotrexate,
tamoxifen, nitrous oxide anesthesia, or anticonvulsant drugs
within the last month as these could inﬂuence homocysteine
concentrations.
Venous blood samples for hsCRP and homocysteine
measurements were obtained from the patients on 2nd, 5th,
and 10th days. The serum was separated within the hour
by centrifugation at 5000rpm for 10minutes. The separated
sera were kept at −70◦C until the laboratory evaluation. The
control group provided a single venous blood sample.
HsCRP was studied by the nefelometric method with an
hsCRP kit (Dade Behring. USA) on the Behring Nephelome-
ter 100 Analyzer and the results were expressed as mg/L. The
limit of detection for CRP is 0.175mg/L. The homocysteine
level was studied with ﬂuorescent detectors using the “high
performance liquid chromatography (HPLC)” method with
theClinRepkitHPLC,Recipechemicals-InstrumentsGmbH
Labortechnik, Munich, Germany and the results were ex-
pressed as µmol/L. The determination of homocysteine in
plasma is linear within a range of 1 to100µmol/L and lower
detection limit is 0.5µmol/L.
The results of the groups were expressed as mean ± stan-
dard deviation. The data produced during the study were
evaluated on the SPSS 12.0 package software program using
the Mann-Whitney U test, chi square test, Spearman corre-
lation test, and Kruscal-Wallis test. A P value <. 05 was con-
sidered signiﬁcant.
3. RESULTS
Seven of the 40 patients died during the study period. Fifteen
of the remaining 33 patients were able to walk independently
at the end of the study period (group A) while 18 patients
could not (group B). The 2nd day’s SSS scores of died pa-
tients(13.7±5.7)weresigniﬁcantlylowerthanlivingpatients
(28.3±14.7, P<. 05). SSS scores of patients increased gradu-
ally and the highest mean scores were determined at the 10th
day of illness (36.0 ± 16.0, P<. 05). The increase in the SSS
score among the evaluation days was statistically signiﬁcant
(P<. 05). The mean SSS scores of patients were shown in
Table 1.
The hsCRP levels following the stroke increased from the
2nd day to the 5th day in a signiﬁcant manner (P<. 05) and
then decreased on the 10th day again in a signiﬁcant manner
(P<. 05). There was no signiﬁcant diﬀerence between the
hsCRP levels in the 2nd day and on the 10th day for hsCRP
levels.
When the patient’s clinical status according to the 2nd
day hsCRP levels was checked, the dying patients had the
highest level (14.7 ± 7.9mg/L) while patients who could
walk had the lowest level (7.1 ± 3.9mg/L) with patients
who could not walk having values between these two levels
(9.2 ± 8.2mg/L). The hsCRP level was signiﬁcantly lower in
the patients who could walk compared to the dying patients
(P<. 005). When the 2nd day’s hsCRP levels of the dying
and surviving patients were compared, the values were sig-
niﬁcantlyhigherinthedyingpatients(14.7±7.9mg/L)com-
pared to the surviving patients (8.2±6.6mg/L, P<. 05). The
mean hsCRP concentration was shown in Table 2.
The diﬀerence between the three mean homocysteine
concentrations of the patient group was not statisticallyTahir Yoldas et al. 3
Table 2: Serum hsCRP levels of study and control groups(a).
hsCRP (mg/L) Patients n = 40 Control n = 40 Clinical status P value
2nd day 9.4 ±7.2— D i e d p a t i e n t s n = 71 4 .7 ±7.0∗ P<. 05
5th day 11.0 ±7.4 — Independent walking n = 15 7.1 ±3.9N S
10th day 9.2 ±7.0 — Nonwalking n = 18 9.2 ±8.3N S
Mean 9.8 ±0.91 .7 ±2.9∗∗ —— P<. 001
(a)Mean ± standard deviation, NS: no signiﬁcant.
Table 3: Serum homocysteine levels of study and control groups(a).
Homocysteine (µmol/L) Patients n = 40 Control n = 40 Clinical status P value
2nd day 20.6 ±9.6— D i e d p a t i e n t s n = 72 0 .3 ±8.2N S
5th day 21.7 ±11.1 — Independent walking n = 15 21.2 ±10.1N S
10th day 20.7 ±9.2 — Nonwalking n = 18 20.5 ±7.2N S
Mean 21.0 ±0.6∗∗ 11.2 ±1.1— — P<. 001
(a)Mean ± standard deviation, NS: no signiﬁcant.
signiﬁcant (P>. 05). There was no statistically signiﬁcant
diﬀerence between the mean homocysteine concentrations
of the dying and surviving patients. It was found that 72.5%
of the patient groups have a homocysteine levels higher than
15µmol/L while it was higher only 25% of the control group
and all of the three mean homocysteinemia concentration of
the patients with ischemic stroke were signiﬁcantly higher
than in healthy control. There was no signiﬁcant diﬀerence
between the female and male patients for homocysteine and
hsCRP levels. The mean hsCRP homocysteine concentration
was shown in Table 3.
No signiﬁcant correlation was found between homocys-
teine and hsCRP levels.
4. DISCUSSION
The most important cause of ischemic strokes is athero-
thrombotic events. Atherosclerosis develops during a long
asymptomatic period and the ﬁrst sign of its existence is an
acute event (MI, stroke) [11]. Laboratory and clinical ev-
idence has shown that systemic inﬂammation plays a role
in every stage from the beginning atherosclerosis to suben-
dothelial lipid deposition [8, 11]. HsCRP is an indication
of the inﬂammatory response to atherosclerosis. It is also a
response to inﬂammation that developing during ischemic
stroke as a result of tissue injury [21]. Beamer et al. [22]
have reported that stroke patients without infection have
increased levels of CRP. Experimental stroke studies have
shown that secretion of inﬂammatory mediators as a direct
response to cerebral injury starts within two hours of focal
ischemia and that occurred anti-inﬂammatory treatment is
also neuroprotective [23–25].
Muir et al. [26] have shown that CRP levels within the
ﬁrst 72 hours following an acute ischemic stroke are an in-
dependent indicator for predicting survival. Our prospective
study showed that the second day hsCRP levels of patients
who died within the ﬁrst 10 days were signiﬁcantly higher
than the surviving patients. It has been reported that a large
infarcts and cortical involvement in patients had a higher
CRPvaluesthannormalatthetimeofpresentation[27].The
same report also suggests that the prognosis is worse in pa-
tients with increased CRP levels. Our ﬁnding that patients
who could walk independently at the end of the study period
have the lowest hsCRP value is also consisted these reports.
The cause of the increased hsCRP in patients who died, and
the lowest hsCRP levels in the walked group may be a indi-
cator of the degree of underlying inﬂammation. Under the
light of our observation and recent literature, our suggestion
is that hsCRP may be a prognostic marker of the prognosis
of these patients.
Inthisstudy,itwasfoundthat72.5%ofthepatientgroup
have a homocysteine levels higher than 15µmol/L while it
was higher only 25% of the control group and all of the
three mean homocysteinemia concentration of the patients
withischemicstrokeweresigniﬁcantlyhigherthaninhealthy
control. Recent studies have shown that acute hyperhomo-
cysteinemia leads to endothelial dysfunction, contributes to
atheroma development [28, 29], and correlates with cerebral
arterial stenosis [30].
Meiklejohn et al. [31] reported that the homocysteine
levels measured in patients with ischemic stroke and tran-
sient ischemic attack in the ﬁrst 24 hours and after three
months did not increase in the acute stage after the
atherothromboticstrokebutincreasedduringconvalescence.
The homocysteine concentrations of the patients were found
to be signiﬁcantly higher than the control group. They have
explained this change in the homocysteine levels as due to
an increase in the homocysteine level in the prestroke peri-
ods which then decrease in the acute phase for unknown rea-
sons. They postulate that this may be a result of changes in
the synthesis of plasma proteins in association with the acute
phase response [31]. However, it is necessary to check ho-
mocysteine levels before and after the stroke to support this4 Mediators of Inﬂammation
hypothesis and it is not possible to predict the development
of stroke.
There are several reports suggesting that mean homo-
cysteine concentrations following a stroke are higher in the
convalescent period than the acute stage, and mild hyperho-
mocysteinemia increased the unfavorable prognosis risk by
11.78 times [32–34]. It seems that increased homocysteine
levels in these patients may be both a cause and also a result
of this process due to acceleration of oxidative stress [32].
In the view of the ﬁndings of the present study there
was no signiﬁcant increase in the homocysteine concentra-
tions in the 10 days following a stroke. We conclude that
homocysteine levels have a limited value for observation of
severity of stroke. Although serum homocysteine was found
to be higher, homocysteine seems not related to prognosis.
Patients with stroke have a higher circulating serum hsCRP
and homocysteine levels. Short term unfavorable prognosis
seems to be associated with elevated serum hsCRP levels in
patients with stroke and may also be able to predict progres-
sion of stroke.
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